Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Gastroesophageal Adenocarcinoma (GEA)
The pooled safety population of ZIIHERA described in WARNINGS AND PRECAUTIONS, reflects exposure to ZIIHERA in combination with chemotherapy, with or without tislelizumab-jsgr, in 725 patients with GEA from four open-label studies, including HERIZON-GEA-01 (N=605), ZWI-ZW25-201 (N=46), ZWI-ZW25-101 (N=41), and BGB-A317-ZW25-101 (N=33) at doses of 1,800 mg every 3 weeks (< 70 kg), 2,400 mg every 3 weeks (≥ 70 kg), 1,200 mg every 2 weeks (< 70 kg), 1,600 mg every 2 weeks (≥ 70 kg), or other doses.
Among the 330 patients who received ZIIHERA in combination with chemotherapy and tislelizumab-jsgr for GEA, 64% were exposed for 6 months or longer, and 41% were exposed for 1 year or more.
Among the 395 patients who received ZIIHERA in combination with chemotherapy for GEA, 57% were exposed for 6 months or longer, and 34% were exposed for 1 year or more.
Biliary Tract Cancer (BTC)
The pooled safety population of ZIIHERA administered 20 mg/kg intravenously as a single agent, described in WARNINGS AND PRECAUTIONS reflects exposure in 233 patients in two single-arm, open-label studies (ZWI-ZW25-101 and HERIZON-BTC-01): 109 patients with biliary tract cancer, and 124 patients with other cancers. Among 233 patients who received ZIIHERA as a single agent, 39% were exposed for 6 months or longer, and 17% were exposed for greater than one year.
Gastroesophageal Adenocarcinoma (GEA) (HERIZON-GEA-01)
The safety of ZIIHERA administered in combination with chemotherapy, with or without tislelizumab-jsgr for the treatment of GEA was evaluated in 901 patients [see Clinical Studies (14.1)].
Patients received ZIIHERA by IV infusion every 3 weeks at 1,800 mg (< 70 kg body weight) or 2,400 mg (≥ 70 kg), with or without tislelizumab-jsgr and an investigator choice of a fluoropyrimidine- and platinum-based chemotherapy (CAPOX or FP) or trastuzumab with CAPOX or FP [see Clinical Studies (14.1)]. Treatment in each arm continued until disease progression or unacceptable toxicity.
ZIIHERA in combination with tislelizumab-jsgr and chemotherapy
Sixty-three percent (63%) of patients were exposed to ZIIHERA for 6 months or longer and 39% 1 year or longer).
Serious adverse reactions occurred in 59% of patients who received ZIIHERA. Serious adverse reactions in > 2% of patients included diarrhea (17%), infusion-related reactions (5%), vomiting (4.8%), hypokalemia (4.4%), acute kidney injury (3.7%), pneumonia (3.7%), nausea (2.4%), decreased appetite (2.4%), and anemia (2.4%). Fatal adverse reactions occurred in 2.4% of patients who received ZIIHERA in combination with tislelizumab-jsgr and chemotherapy include acute kidney injury (N=2), cardiac failure, diarrhea, dehydration, hypovolemic shock and intestinal obstruction (all N=1).
Permanent discontinuation of ZIIHERA occurred in 13% of patients. Adverse reactions that resulted in permanent discontinuation of ZIIHERA in ≥ 1% of patients included diarrhea (4.4%) and ejection fraction decreased (2.7%).
Dosage interruptions of ZIIHERA, excluding temporary interruptions of ZIIHERA infusions due to infusion-related reactions, occurred in 65% of patients. Adverse reactions requiring a dose interruption of ZIIHERA in > 3% of patients, excluding infusion-related reactions, were diarrhea (14%), neutropenia (11%), platelet count decreased (9%), fatigue (7%), ejection fraction decreased (7%), anemia (6%), hypokalemia (4.8%), decreased appetite (4.4%), vomiting (3.4%), and rash (3.1%).
Dosage reductions of ZIIHERA occurred in 14% of patients. The adverse reactions requiring dosage reduction of ZIIHERA in ≥ 1% of patients were diarrhea (10%) and hypokalemia (1.0%).
The most common adverse reactions (≥ 20%) were diarrhea (83%), nausea (56%), decreased appetite (46%), vomiting (44%), hypokalemia (39%), fatigue (37%), rash (36%), peripheral neuropathy (27%), and infusion-related reaction (25%).
ZIIHERA in combination with chemotherapy
Fifty-seven percent (57%) of patients were exposed to ZIIHERA for 6 months or longer and 32% for 1 year or longer.
Serious adverse reactions occurred in 49% of patients who received ZIIHERA. Serious adverse reactions in > 2% of patients included diarrhea (11%), vomiting (3.3%), decreased appetite (2.6%), pneumonia (2.6%), sepsis (2.6%), hypokalemia (2.3%), and nausea (2.3%).
Permanent discontinuation of ZIIHERA occurred in 10% of patients. Adverse reactions that resulted in permanent discontinuation of ZIIHERA in ≥ 1% of patients included ejection fraction decreased (2.0%), infusion-related reaction (1.6%), and diarrhea (1.6%).
Dosage interruptions of ZIIHERA, excluding temporary interruptions of ZIIHERA infusions due to infusion-related reactions, occurred in 56% of patients. Adverse reactions requiring a dose interruption of ZIIHERA, excluding infusion-related reactions, occurring in > 3% of patients were diarrhea (14%), neutropenia (10%), platelet count decreased (10%), anemia (6%), ejection fraction decreased (6%), fatigue (6%), and hypokalemia (3.9%).
Dosage reductions of ZIIHERA occurred in 15% of patients who received ZIIHERA in combination with chemotherapy. Adverse reactions requiring dosage reductions of ZIIHERA in ≥ 1% of patients were diarrhea (11%), decreased appetite (1.0%), and ejection fraction decreased (1.0%).
The most common adverse reactions in patients receiving ZIIHERA in combination with chemotherapy (≥ 20%) were diarrhea (79%), nausea (54%), vomiting (44%), decreased appetite (40%), fatigue (36%), hypokalemia (33%), peripheral neuropathy (32%), infusion-related reaction (25%), and rash (22%).
Table 5 summarizes the adverse reactions in HERIZON-GEA-01.
Table 5: Adverse Reactions (≥ 10%) With an Increased Incidence (≥ 5% Increase in All Grades) in a ZIIHERA-containing arm in HERIZON-GEA-01Adverse Reaction* | ZIIHERA with chemotherapy and tislelizumab-jsgr N = 294 | ZIIHERA with chemotherapy N = 305 | Trastuzumab with chemotherapy N = 302 |
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
Gastrointestinal disorders |
Diarrheaa | 83 | 26 | 79 | 21 | 53 | 14 |
Nausea | 56 | 8 | 54 | 4.3 | 48 | 3.0 |
Vomitingb | 44 | 6 | 44 | 3.6 | 34 | 4.3 |
Metabolism and nutrition disorders |
Decreased appetite | 46 | 8 | 40 | 7 | 36 | 6 |
General disorders and administration site conditions |
Fatiguec | 37 | 7 | 36 | 7 | 30 | 6 |
Skin and subcutaneous tissue disorders |
Rashd | 36 | 5 | 22 | 2.6 | 25 | 5 |
Pruritus | 17 | 0.7 | 8 | 0.3 | 3.6 | 0 |
Injury, poisoning, and procedural complications |
Infusion-related reaction | 25 | 1.7 | 25 | 2.3 | 13 | 0.7 |
Investigations |
Ejection fraction decreasede | 12 | 3.1 | 9 | 2.3 | 7 | 1.3 |
* Graded per CTCAE version 5.
a Diarrhea includes colitis, diarrhea, enteritis, enterocolitis and enterocolitis hemorrhagic.
b Vomiting includes hematemesis and vomiting.
c Fatigue includes asthenia and fatigue.
d Rash includes dermatitis, dermatitis acneiform, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash maculo-papular, rash pustular and urticaria.
e Ejection fraction decreased includes cardiac failure, ejection fraction decreased, left ventricular dysfunction and right ventricular failure.
Table 6 summarizes the laboratory abnormalities in HERIZON‑GEA‑01.
Table 6: Laboratory Abnormalities (≥ 30%) with an Increased Incidence (at least 5% of all Grades or 2% Grade 3-4) in a ZIIHERA-containing arm in HERIZON-GEA-01Laboratory Abnormalities | ZIIHERA with chemotherapy and tislelizumab-jsgr N = 294 | ZIIHERA with chemotherapy N = 305 | Trastuzumab with chemotherapy N = 302 |
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
Hematology |
Hemoglobin decreased | 97 | 19 | 92 | 16 | 92 | 16 |
Chemistry |
Potassium decreased | 61 | 27 | 56 | 23 | 38 | 12 |
Blood calcium decreased | 62 | 1.7 | 52 | 1.6 | 56 | 1.7 |
Aspartate aminotransferase increased | 51 | 4.8 | 46 | 2.3 | 53 | 0.7 |
Blood magnesium decreased | 42 | 0.3 | 43 | 3 | 24 | 0 |
Alanine aminotransferase increased | 41 | 3.4 | 38 | 1.6 | 37 | 0 |
Sodium decreased | 43 | 2 | 35 | 2.3 | 35 | 1 |
Creatinine increased | 34 | 4.1 | 23 | 2.6 | 21 | 2.3 |
Biliary Tract Cancer (HERIZON-BTC-01)
The safety of ZIIHERA was evaluated in 80 patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer who received at least one prior gemcitabine-containing chemotherapy regimen in HERIZON-BTC-01 [see Clinical Studies (14.2)]. Patients received ZIIHERA 20 mg/kg by IV infusion once every 2 weeks until disease progression or unacceptable toxicity. The median duration of exposure to ZIIHERA was 5.6 months (range: 0.5 to 27.2 months).
Serious adverse reactions occurred in 54% of patients who received ZIIHERA. Serious adverse reactions in > 2% of patients included biliary obstruction (15%), biliary tract infection (8%), sepsis (8%), pneumonia (5%), diarrhea (3.8%), gastric obstruction (3.8%), and fatigue (2.5%). A fatal adverse reaction of hepatic failure occurred in one patient who received ZIIHERA.
Permanent discontinuation due to an adverse reaction occurred in 2.5% of patients who received ZIIHERA. Adverse reactions which resulted in permanent discontinuation in ≥ 1% of patients who received ZIIHERA included decreased ejection fraction and pneumonitis.
Dosage interruptions due to adverse reactions, excluding temporary interruptions of ZIIHERA infusions due to infusion-related reactions, occurred in 41% of patients who received ZIIHERA. The most frequent adverse reactions (> 2% of patients) that required dosage interruption were diarrhea, increased alanine aminotransferase, increased aspartate aminotransferase, decreased ejection fraction, pneumonia, cholangitis, fatigue, biliary obstruction, abdominal pain, increased blood creatinine, and decreased potassium.
Dosage reductions due to an adverse reaction occurred in 4% of patients who received ZIIHERA. Adverse reactions requiring dosage reductions in > 1% of patients were diarrhea, nausea, and decreased weight.
The most common adverse reactions in patients receiving ZIIHERA (≥ 20%) were diarrhea, infusion-related reaction, abdominal pain, and fatigue.
Table 7 summarizes the adverse reactions that occurred in HERIZON-BTC-01.
Table 7: Adverse Reactions (≥ 15%) in HERIZON-BTC-01Adverse Reaction* | ZIIHERA N=80 |
All Grades (%) | Grades 3 or 4 (%) |
Gastrointestinal disorders |
Diarrheaa | 50 | 10 |
Abdominal painb | 29 | 1 |
Nausea | 18 | 1 |
Vomiting | 15 | 1 |
Injury, poisoning, and procedural complications |
Infusion-related reaction | 35 | 1 |
General disorders and administration site conditions |
Fatiguec | 24 | 4 |
Skin and subcutaneous tissue disorders |
Rashd | 19 | 0 |
Metabolism and nutrition disorders |
Decreased appetite | 16 | 0 |
* Graded per CTCAE version 5.
a Diarrhea includes diarrhea and enteritis
b Abdominal pain includes abdominal pain and abdominal pain upper
c Fatigue includes asthenia and fatigue
d Rash includes dermatitis, dermatitis acneiform, palmar-plantar erythrodysesthesia syndrome, rash, rash maculo-papular, and rash pustular
Table 8 summarizes the laboratory abnormalities in HERIZON-BTC-01.
Table 8: Laboratory Abnormalities (≥ 30%) that Worsened from Baseline in Patients with Unresectable or Metastatic HER2-Positive BTC Receiving ZIIHERA in HERIZON-BTC-01Laboratory Abnormalities | ZIIHERA* |
All Grades (%) | Grades 3 or 4 (%) |
Hematology |
Hemoglobin decreased | 88 | 14 |
Lymphocytes decreased | 44 | 8 |
Chemistry |
Lactate dehydrogenase increased | 55 | 0 |
Albumin decreased | 53 | 0 |
Aspartate aminotransferase increased | 47 | 10 |
Alanine aminotransferase increased | 46 | 8 |
Alkaline phosphatase increased | 41 | 5 |
Sodium decreased | 35 | 10 |
Potassium decreased | 34 | 5 |
* The denominator used to calculate the rate varied from 78 to 80 based on the number of patients with a baseline value and at least one post-treatment value.